NanoFUSE Biologics cracks Asian market with successful procedure in Thailand

Alan Condon -   Print  |

NanoFuse Biologics expanded into Asia after the successful use of its technology in a patient suffering from degenerative spine disease and osteoporosis in Thailand.

Thai neurosurgeon Dr. Teera Tangviriyabiaboon completed the operation on an 80-year-old patient who failed conservative treatments prior to surgery.

Dr. Tangviriyabiaboon said the technology was easy to use and is "expected to maximize success of spine fusion as the only approved demineralized bone matrix and bioactive glass combination biologic."

"NanoFUSE is clinically proven and reduces the need for autograft," said Jake Lubinski, president of NanoFuse. "The recent release of our 100 percent fully synthetic bioactive glass strip, NanoStrip positions NanoFuse to be the worldwide leader in bioactive glass and synthetic biologics."

More articles on biologics:
DiscGenics tests injectable disc cell therapy for degenerative disc disease
Federal court bans Florida stem cell company from treating patients, including spinal cord injury
NervGen Pharma launches MS program focusing on nerve remyelination — 3 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers